Abstract
Insulin-like growth factor-I (IGF-I) is a naturally occurring single chain polypeptide of 7649 Da that is produced primarily in the liver. The metabolic activities of IGF-I are similar to those of insulin and its effects on growth, development, regeneration and metabolism have been widely studied. Indeed, IGF-I is currently being used clinically for the treatment of growth related disorders and its therapeutic value is also being evaluated in diabetes, IGF-I-induced neuroprotection, and in promoting bone healing. However, like many other peptides, IGF-I has a short biological half-life and is rapidly removed from circulation following systemic administration. In the vascular system, this is normally compensated for by the association of IGF-I with IGF-binding proteins (IGFBPs), that also appear to regulate the activities of IGF-I. Here, we describe the biopharmaceutical properties of different parenteral formulations of IGF-I. The pharmaceutical characteristics of conventional formulations such as aqueous IGF-I solutions are compare with new controlled release formulations such as multivesicular liposomes, osmotic minipumps, and poly (DL-lactic-co-glycolic) acid (PLGA) microspheres.
Keywords: rhIgf-I, activity, pharmacology, therapeutics, pharmacokinetics, bioavailability, parenteral, controlled release
Current Pharmaceutical Biotechnology
Title: Pharmacological Characteristics of Parenteral IGF-I Administration
Volume: 4 Issue: 2
Author(s): J. Torrado and C. Carrascosa
Affiliation:
Keywords: rhIgf-I, activity, pharmacology, therapeutics, pharmacokinetics, bioavailability, parenteral, controlled release
Abstract: Insulin-like growth factor-I (IGF-I) is a naturally occurring single chain polypeptide of 7649 Da that is produced primarily in the liver. The metabolic activities of IGF-I are similar to those of insulin and its effects on growth, development, regeneration and metabolism have been widely studied. Indeed, IGF-I is currently being used clinically for the treatment of growth related disorders and its therapeutic value is also being evaluated in diabetes, IGF-I-induced neuroprotection, and in promoting bone healing. However, like many other peptides, IGF-I has a short biological half-life and is rapidly removed from circulation following systemic administration. In the vascular system, this is normally compensated for by the association of IGF-I with IGF-binding proteins (IGFBPs), that also appear to regulate the activities of IGF-I. Here, we describe the biopharmaceutical properties of different parenteral formulations of IGF-I. The pharmaceutical characteristics of conventional formulations such as aqueous IGF-I solutions are compare with new controlled release formulations such as multivesicular liposomes, osmotic minipumps, and poly (DL-lactic-co-glycolic) acid (PLGA) microspheres.
Export Options
About this article
Cite this article as:
Torrado J. and Carrascosa C., Pharmacological Characteristics of Parenteral IGF-I Administration, Current Pharmaceutical Biotechnology 2003; 4 (2) . https://dx.doi.org/10.2174/1389201033489865
DOI https://dx.doi.org/10.2174/1389201033489865 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cardiovascular Risk in Patients with Primary Hyperparathyroidism
Current Pharmaceutical Design Phosphodiesterase 5 Inhibitors - Drug Design and Differentiation Based on Selectivity, Pharmacokinetic and Efficacy Profiles
Current Pharmaceutical Design Imidazole: An Essential Edifice for the Identification of New Lead Compounds and Drug Development
Mini-Reviews in Medicinal Chemistry Advances in the Treatment of Neurodegenerative Disorders Employing Nanoparticles
Recent Patents on Drug Delivery & Formulation A Comprehensive Review on Phytochemistry and Pharmacological Effects of Stinging Nettle (Urtica dioica)
Current Traditional Medicine Perioperative B-blockers in Non-cardiac Surgery: Actual Situation
Current Pharmaceutical Design Hydrogen Sulfide: From Physiology to Pharmacology
Inflammation & Allergy - Drug Targets (Discontinued) The Renin-Angiotensin System: Emerging Concepts
Current Hypertension Reviews New Insight Into A1 Adenosine Receptors in Diabetes Treatment
Current Pharmaceutical Design Central Nervous System Agents Used as Trypanosoma cruzi Infection Chemotherapy: Phenothiazines and Related Compounds
Current Medicinal Chemistry - Anti-Infective Agents Diagnosing and Treating Depression in Older and Oldest Old
Current Pharmaceutical Design Hirsutism in Polycystic Ovary Syndrome: Pathophysiology and Management
Current Pharmaceutical Design Beta-Blockers in Pediatric Hypertrophic Cardiomyopathies
Reviews on Recent Clinical Trials An Updated Patent Review on Ocular Drug Delivery Systems with Potential for Commercial Viability
Recent Patents on Drug Delivery & Formulation Addressing Unmet Medical Needs in Type 2 Diabetes: A Narrative Review of Drugs under Development
Current Diabetes Reviews New Developments in Therapeutic Agents for Legionnaires Disease
Anti-Infective Agents in Medicinal Chemistry Ganoderma lucidum: A Potential for Biotechnological Production of Anti-Cancer and Immunomodulatory Drugs
Recent Patents on Anti-Cancer Drug Discovery Targeting Vascular Niche by Parathyroid Hormone
Current Medicinal Chemistry Mutations in PRKN and SNCA Genes Important for the Progress of Parkinson’s Disease
Current Genomics Immunotherapy for Food Allergies in Children
Current Pharmaceutical Design